HaemaLogiX Ltd Information

HaemaLogiX focus is the development and commercialisation of novel immuno-oncology and immune-therapies. HaemaLogiX is embarking on a program of several inter-related research and clincial development projects that will validate the antigen targets and products. We have a unique opportunity to develop effective treatments that improve the quality of life of patients suffering from blood cancers and autoimmune diseases.

Website	http://www.haemalogix.com
Revenue	$5.8 million
Employees	7 (4 on RocketReach)
Founded	2014
Address	Level 3, 343 George St, Suite 306, Sydney, New South Wales 2000, AU
Technologies	JavaScript , HTML , Twitter +10 more (view full list)
Industry	Biotechnology, Business Services General, Health Care, Business Services, Life Science, Science and Engineering, Medical
Keywords	Therapeutic Antibodies, Cancer Therapies, Novel Therapies, Oncology Drugs, Cell Therapy, Immunotherapy Research, Clinical Development, Targeted Therapies, Biotechnology, Pharmaceutical Research, Biopharma, Drug Development, Immunology, Oncology Research, Cancer Research, Preclinical Development
Competitors	Thermo Fisher Scientific, Roche, Beckman Coulter Diagnostics, Abbott, Siemens Healthineers, Bio-Rad Laboratories, Merck KGaA, Darmstadt, Germany, Ortho Clinical Diagnostics - ANZ, Sysmex America, Inc., BD +32 more (view full list)
SIC	SIC Code 283 Companies, SIC Code 873 Companies, SIC Code 87 Companies, SIC Code 28 Companies
NAICS	NAICS Code 32541 Companies, NAICS Code 54 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 541 Companies, NAICS Code 325414 Companies, NAICS Code 3254 Companies